Skip to main content
. 2019 Mar 1;8(4):318–325. doi: 10.1530/EC-18-0523

Table 3.

Secondary efficacy measurements from baseline to week 12. Data were means ± s.d. or medians (interquartile ranges) for skewed variables or numbers (proportions) for categorical variables.

Sitagliptin (N = 93) Vildagliptin (N = 94) Saxagliptin (N = 90) P* value
BMI (kg/m2) change −0.5 ± 1.9 −0.1 ± 0.7 0.3 ± 0.8 0.41
TC (mmol/L) change 0.1 (−0.4 to 0.4) −0.1 (−0.5 to 0.5) 0.5 (0.2–1.0) 0.01
LDL-C (mmol/L) change −0.2 ± 0.8 −0.2 ± 1.1 0.3 ± 1.1 0.05
HDL-C (mmol/L) change −0.00 ± 0.2 0.06 ± 0.4 0.02 ± 1.6 0.99
ALT (IU/L) change 0.5 (−1.0 to 5.0) 0.65 (−7.3 to 4.4) 6.0 (0.0–20.2) 0.08
AST (IU/L) change 1.0 (−2.0 to 5.0) −2.6 (−8.1 to 1.1) 1.5 (−1.0 to 6.2) 0.42
Cr (µmol/L) change −1.1 ± 9.4 2.3 ± 11.7 −2.8 ± 8.0 0.70
BIL (µmol/L) change 8.1 ± 34.0 1.2 ± 6.7 0.9 ± 5.7 0.42
WBC (109/L) change −0.2 ± 2.0 −0.3 ± 2.1 0.05 ± 2.1 0.62

P value was calculated for Chi-square test across the three groups. P < 0.05 was considered to be statistically significant.

*Age and HbA1c-adjusted P value.

BMI, body mass index; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Cr, creatine; BIL, total bilirubin; WBC, white blood cell.